User login
Adjuvant osimertinib extends DFS in localized NSCLC
, results of the ADAURA trial showed.
The randomized, phase 3 trial was a comparison of osimertinib treatment with placebo following complete resection of localized or locally advanced NSCLC with negative margins. The trial was unblinded early and halted on the recommendation of the independent data-monitoring committee, due to the efficacy of osimertinib.
“If I were on the committee, I would have done the same thing. These are extraordinary results,” said study investigator Roy S. Herbst, MD, PhD, chief of medical oncology at the Yale Cancer Center and Smilow Cancer Center at Yale University in New Haven, Conn.
Dr. Herbst is scheduled to present results from ADAURA as part of the American Society of Clinical Oncology virtual scientific program.
In an online briefing prior to the meeting, Dr. Herbst said the impressive results reminded him of a lesson imparted by his mentor, the late Isaiah Fidler, DVM, PhD.
“He taught me, he taught all of us, that metastasis is a spread of tumor that kills patients,” Dr. Herbst said. “Drugs such as this, based on biology, given to patients at the earliest possible time, prevent those metastases and allow patients to live longer and with a better quality of life.”
Results from the ADAURA trial provide compelling evidence of the benefit of adjuvant osimertinib for a select group of patients, according to Tina Cascone, MD, PhD, assistant professor in the department of thoracic head and neck medical oncology at The University of Texas MD Anderson Cancer Center in Houston. She was not involved in the study.
“These are unprecedented results for a potentially curable, resected population of patients,” Dr. Cascone said in an interview. “This definitely has the potential to shift the paradigm in the treatments that we have available for patients with resected disease. It’s very important to emphasize how much we’ve learned from the metastatic setting and how we’re bringing what we’ve learned into early stage disease.”
High recurrence rates
An estimated 30% of patients with NSCLC present with resectable disease at diagnosis, but 5-year recurrence rates following surgery and cisplatin-based adjuvant chemotherapy remain high, ranging from 45% among patients with stage IB disease to 62% for patients with stage II NSCLC and 76% for patients with stage III disease, Dr. Herbst noted.
Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) targeted to EGFR. It has been shown to offer improvements in both progression-free survival and overall survival compared with the EGFR-TKIs erlotinib and gefitinib for patients with advanced EGFR-mutated NSCLC, as well as in patients with central nervous system metastases.
Osimertinib’s efficacy and safety profile against advanced disease suggests it may also be effective against early stage disease, a hypothesis the ADAURA trial was designed to test.
Study details
The phase 3, randomized, double-blind trial was conducted at centers in the United States, Europe, Asia, and Australia. A total of 682 patients with completely resected stage IB, II, or IIIA NSCLC, with or without planned adjuvant chemotherapy, were enrolled.
After stratification by stage, EGFR mutation, and race (Asian vs. non-Asian), patients were randomized on a 1:1 basis to receive either osimertinib at 80 mg once daily or placebo. The planned treatment duration was a maximum of 3 years.
Members of the independent data-monitoring committee held a meeting in April 2020. Although they had not planned an efficacy analysis at that time, they decided the results were clearly in favor of osimertinib. So they recommended unblinding and halting of the trial.
At the time of unblinding, the study had completed enrollment, and all patients had been followed for at least 1 year.
Efficacy and safety
For the primary endpoint of disease-free survival (DFS) in patients with stage II to IIIA disease, the median DFS was not reached for patients assigned to osimertinib, but it was 20.4 months for patients assigned to placebo (hazard ratio, 0.17; P < .0001).
The numbers were similar for the secondary endpoint of DFS in the overall population, including patients with stage IB disease. The median DFS was not reached for patients on osimertinib but was 28.1 months for patients on placebo (HR, 0.21; P < .0001).
DFS was significantly superior with osimertinib across all subgroups in the overall population, including sex, age, smoking status, race, stage, EGFR mutation, and adjuvant chemotherapy (yes or no).
Dr. Herbst said patients tolerated osimertinib well, and the drug’s safety profile was consistent with that already known. There were no adverse events leading to death in the osimertinib arm, and the incidence of grade 3 or 4 adverse events of any kind was low.
In all, 10 patients (3%) in the osimertinib arm were reported to have interstitial lung disease. Prolongation of the QT interval was reported in 22 patients (7%) on osimertinib and 4 patients (1%) in the placebo arm.
The results show that “adjuvant osimertinib provides a highly effective, practice-changing treatment for patients with stage IB, II, IIIA, EGFR mutation-positive non–small cell lung cancer after complete tumor resection,” Dr. Herbst said.
Dr. Herbst disclosed relationships with AstraZeneca, which funded the study, as well as Jun Shi Pharmaceuticals and other companies. Dr. Cascone is the international principal investigator of the NeoCOAST trial evaluating durvalumab, an AstraZeneca product.
SOURCE: Herbst RS et al. ASCO 2020, Abstract LBA5.
, results of the ADAURA trial showed.
The randomized, phase 3 trial was a comparison of osimertinib treatment with placebo following complete resection of localized or locally advanced NSCLC with negative margins. The trial was unblinded early and halted on the recommendation of the independent data-monitoring committee, due to the efficacy of osimertinib.
“If I were on the committee, I would have done the same thing. These are extraordinary results,” said study investigator Roy S. Herbst, MD, PhD, chief of medical oncology at the Yale Cancer Center and Smilow Cancer Center at Yale University in New Haven, Conn.
Dr. Herbst is scheduled to present results from ADAURA as part of the American Society of Clinical Oncology virtual scientific program.
In an online briefing prior to the meeting, Dr. Herbst said the impressive results reminded him of a lesson imparted by his mentor, the late Isaiah Fidler, DVM, PhD.
“He taught me, he taught all of us, that metastasis is a spread of tumor that kills patients,” Dr. Herbst said. “Drugs such as this, based on biology, given to patients at the earliest possible time, prevent those metastases and allow patients to live longer and with a better quality of life.”
Results from the ADAURA trial provide compelling evidence of the benefit of adjuvant osimertinib for a select group of patients, according to Tina Cascone, MD, PhD, assistant professor in the department of thoracic head and neck medical oncology at The University of Texas MD Anderson Cancer Center in Houston. She was not involved in the study.
“These are unprecedented results for a potentially curable, resected population of patients,” Dr. Cascone said in an interview. “This definitely has the potential to shift the paradigm in the treatments that we have available for patients with resected disease. It’s very important to emphasize how much we’ve learned from the metastatic setting and how we’re bringing what we’ve learned into early stage disease.”
High recurrence rates
An estimated 30% of patients with NSCLC present with resectable disease at diagnosis, but 5-year recurrence rates following surgery and cisplatin-based adjuvant chemotherapy remain high, ranging from 45% among patients with stage IB disease to 62% for patients with stage II NSCLC and 76% for patients with stage III disease, Dr. Herbst noted.
Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) targeted to EGFR. It has been shown to offer improvements in both progression-free survival and overall survival compared with the EGFR-TKIs erlotinib and gefitinib for patients with advanced EGFR-mutated NSCLC, as well as in patients with central nervous system metastases.
Osimertinib’s efficacy and safety profile against advanced disease suggests it may also be effective against early stage disease, a hypothesis the ADAURA trial was designed to test.
Study details
The phase 3, randomized, double-blind trial was conducted at centers in the United States, Europe, Asia, and Australia. A total of 682 patients with completely resected stage IB, II, or IIIA NSCLC, with or without planned adjuvant chemotherapy, were enrolled.
After stratification by stage, EGFR mutation, and race (Asian vs. non-Asian), patients were randomized on a 1:1 basis to receive either osimertinib at 80 mg once daily or placebo. The planned treatment duration was a maximum of 3 years.
Members of the independent data-monitoring committee held a meeting in April 2020. Although they had not planned an efficacy analysis at that time, they decided the results were clearly in favor of osimertinib. So they recommended unblinding and halting of the trial.
At the time of unblinding, the study had completed enrollment, and all patients had been followed for at least 1 year.
Efficacy and safety
For the primary endpoint of disease-free survival (DFS) in patients with stage II to IIIA disease, the median DFS was not reached for patients assigned to osimertinib, but it was 20.4 months for patients assigned to placebo (hazard ratio, 0.17; P < .0001).
The numbers were similar for the secondary endpoint of DFS in the overall population, including patients with stage IB disease. The median DFS was not reached for patients on osimertinib but was 28.1 months for patients on placebo (HR, 0.21; P < .0001).
DFS was significantly superior with osimertinib across all subgroups in the overall population, including sex, age, smoking status, race, stage, EGFR mutation, and adjuvant chemotherapy (yes or no).
Dr. Herbst said patients tolerated osimertinib well, and the drug’s safety profile was consistent with that already known. There were no adverse events leading to death in the osimertinib arm, and the incidence of grade 3 or 4 adverse events of any kind was low.
In all, 10 patients (3%) in the osimertinib arm were reported to have interstitial lung disease. Prolongation of the QT interval was reported in 22 patients (7%) on osimertinib and 4 patients (1%) in the placebo arm.
The results show that “adjuvant osimertinib provides a highly effective, practice-changing treatment for patients with stage IB, II, IIIA, EGFR mutation-positive non–small cell lung cancer after complete tumor resection,” Dr. Herbst said.
Dr. Herbst disclosed relationships with AstraZeneca, which funded the study, as well as Jun Shi Pharmaceuticals and other companies. Dr. Cascone is the international principal investigator of the NeoCOAST trial evaluating durvalumab, an AstraZeneca product.
SOURCE: Herbst RS et al. ASCO 2020, Abstract LBA5.
, results of the ADAURA trial showed.
The randomized, phase 3 trial was a comparison of osimertinib treatment with placebo following complete resection of localized or locally advanced NSCLC with negative margins. The trial was unblinded early and halted on the recommendation of the independent data-monitoring committee, due to the efficacy of osimertinib.
“If I were on the committee, I would have done the same thing. These are extraordinary results,” said study investigator Roy S. Herbst, MD, PhD, chief of medical oncology at the Yale Cancer Center and Smilow Cancer Center at Yale University in New Haven, Conn.
Dr. Herbst is scheduled to present results from ADAURA as part of the American Society of Clinical Oncology virtual scientific program.
In an online briefing prior to the meeting, Dr. Herbst said the impressive results reminded him of a lesson imparted by his mentor, the late Isaiah Fidler, DVM, PhD.
“He taught me, he taught all of us, that metastasis is a spread of tumor that kills patients,” Dr. Herbst said. “Drugs such as this, based on biology, given to patients at the earliest possible time, prevent those metastases and allow patients to live longer and with a better quality of life.”
Results from the ADAURA trial provide compelling evidence of the benefit of adjuvant osimertinib for a select group of patients, according to Tina Cascone, MD, PhD, assistant professor in the department of thoracic head and neck medical oncology at The University of Texas MD Anderson Cancer Center in Houston. She was not involved in the study.
“These are unprecedented results for a potentially curable, resected population of patients,” Dr. Cascone said in an interview. “This definitely has the potential to shift the paradigm in the treatments that we have available for patients with resected disease. It’s very important to emphasize how much we’ve learned from the metastatic setting and how we’re bringing what we’ve learned into early stage disease.”
High recurrence rates
An estimated 30% of patients with NSCLC present with resectable disease at diagnosis, but 5-year recurrence rates following surgery and cisplatin-based adjuvant chemotherapy remain high, ranging from 45% among patients with stage IB disease to 62% for patients with stage II NSCLC and 76% for patients with stage III disease, Dr. Herbst noted.
Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) targeted to EGFR. It has been shown to offer improvements in both progression-free survival and overall survival compared with the EGFR-TKIs erlotinib and gefitinib for patients with advanced EGFR-mutated NSCLC, as well as in patients with central nervous system metastases.
Osimertinib’s efficacy and safety profile against advanced disease suggests it may also be effective against early stage disease, a hypothesis the ADAURA trial was designed to test.
Study details
The phase 3, randomized, double-blind trial was conducted at centers in the United States, Europe, Asia, and Australia. A total of 682 patients with completely resected stage IB, II, or IIIA NSCLC, with or without planned adjuvant chemotherapy, were enrolled.
After stratification by stage, EGFR mutation, and race (Asian vs. non-Asian), patients were randomized on a 1:1 basis to receive either osimertinib at 80 mg once daily or placebo. The planned treatment duration was a maximum of 3 years.
Members of the independent data-monitoring committee held a meeting in April 2020. Although they had not planned an efficacy analysis at that time, they decided the results were clearly in favor of osimertinib. So they recommended unblinding and halting of the trial.
At the time of unblinding, the study had completed enrollment, and all patients had been followed for at least 1 year.
Efficacy and safety
For the primary endpoint of disease-free survival (DFS) in patients with stage II to IIIA disease, the median DFS was not reached for patients assigned to osimertinib, but it was 20.4 months for patients assigned to placebo (hazard ratio, 0.17; P < .0001).
The numbers were similar for the secondary endpoint of DFS in the overall population, including patients with stage IB disease. The median DFS was not reached for patients on osimertinib but was 28.1 months for patients on placebo (HR, 0.21; P < .0001).
DFS was significantly superior with osimertinib across all subgroups in the overall population, including sex, age, smoking status, race, stage, EGFR mutation, and adjuvant chemotherapy (yes or no).
Dr. Herbst said patients tolerated osimertinib well, and the drug’s safety profile was consistent with that already known. There were no adverse events leading to death in the osimertinib arm, and the incidence of grade 3 or 4 adverse events of any kind was low.
In all, 10 patients (3%) in the osimertinib arm were reported to have interstitial lung disease. Prolongation of the QT interval was reported in 22 patients (7%) on osimertinib and 4 patients (1%) in the placebo arm.
The results show that “adjuvant osimertinib provides a highly effective, practice-changing treatment for patients with stage IB, II, IIIA, EGFR mutation-positive non–small cell lung cancer after complete tumor resection,” Dr. Herbst said.
Dr. Herbst disclosed relationships with AstraZeneca, which funded the study, as well as Jun Shi Pharmaceuticals and other companies. Dr. Cascone is the international principal investigator of the NeoCOAST trial evaluating durvalumab, an AstraZeneca product.
SOURCE: Herbst RS et al. ASCO 2020, Abstract LBA5.
FROM ASCO 2020
Key clinical point: Adjuvant osimertinib extended disease-free survival, compared with placebo, in patients with EGFR-mutated non–small cell lung cancer.
Major finding: In the overall population, the median disease-free survival was not reached for patients on osimertinib and was 28.1 months for patients on placebo (hazard ratio, 0.21, P < .0001).
Study details: Randomized, double-blind, phase 3 trial of 682 patients with stage IB-IIIA non–small cell lung cancer bearing EGFR mutations.
Disclosures: Dr. Herbst disclosed relationships with AstraZeneca, which funded the study, as well as Jun Shi Pharmaceuticals and other companies.
Source: Herbst RS et al. ASCO 2020, Abstract LBA5.
Quitting smoking just 2 years before lung cancer diagnosis may improve survival
Quitting smoking prior to a lung cancer diagnosis is associated with a survival benefit, even among patients who recently stopped smoking, according to results of a pooled analysis.
The overall survival advantage was significant regardless of how long ago patients had last smoked, including among those who quit within 2 years prior to their diagnosis.
These findings create a “teachable moment” for health care providers in scenarios when patients might be more receptive to a stop-smoking message, according to investigator Aline F. Fares, MD, a clinical research fellow at Princess Margaret Cancer Centre in Toronto.
“Our study can be summarized to patients as, ‘it’s never too late to quit,’ ” Dr. Fares said.
She presented results from this study at the American Society of Clinical Oncology virtual scientific program during a press briefing in advance of the meeting. This year, ASCO’s annual meeting is split into two parts. The virtual scientific program will be presented online May 29-31. The virtual education program will be available Aug. 8-10.
Results
Dr. Fares presented data on 35,481 patients with a diagnosis of lung cancer who had been enrolled in 17 studies conducted by the International Lung Cancer Consortium. (Data in the presentation were updated from the abstract.)
At diagnosis, 47.5% of the patients were current smokers, 30% were former smokers, and 22.5% were never smokers.
The risk of death from any cause was cut by 20% among former smokers who quit more than 5 years before their lung cancer diagnosis (P < .001). Patients who quit smoking 2-5 years before diagnosis had a 16% reduction in the risk of death, while those who quit within 2 years of diagnosis had a 12% reduced risk (P < .001 for both comparisons).
The overall survival advantage was evident in this pooled analysis regardless of patient sex, disease stage, histology, or amount of smoking as measured in pack-years, according to Dr. Fares. That said, the overall survival advantage appeared to be even greater among heavier smokers (i.e., greater than 30 pack-years) as compared with lighter smokers.
Lung cancer–specific survival was improved by 15% for patients who quit smoking more than 5 years prior to their diagnosis. For those who had quit more recently, there was a nonsignificant trend toward improvement in this outcome.
Overall survival was higher in never smokers in comparison with current smokers, a finding that was expected based on previous studies, according to Dr. Fares.
Implications
These findings could be important to share with individuals who are current smokers at the time of lung cancer screening, according to Maher A. Karam-Hage, MD, medical director of the tobacco treatment program at the University of Texas MD Anderson Cancer Center, Houston.
“The power of this data is that it shows quitting makes a difference, and that it can be more impactful the longer you quit before you get diagnosed,” Dr. Karam-Hage said in an interview.
Negative lung cancer screening results sometimes give individuals the false impression that they are “one of the lucky ones” who won’t get lung cancer and don’t have to quit smoking, according to Dr. Karam-Hage, who is studying the comparative effectiveness of different smoking cessation strategies.
“Now, as part of shared decision making, we can provide people with specific numbers before the scan that [suggest] no matter what the scan comes out with, the earlier they quit, the better off they will be,” he said.
In her presentation, Dr. Fares said that lung cancer screening may be an “interesting time” to address smoking cessation, particularly among patients with a heavier smoking history.
“After a lifetime of smoking, patients often feel it’s too late to quit smoking and that the damage has already been done,” she added.
The International Lung Cancer Consortium studies had multiple supporters. Dr. Fares reported having no disclosures related to the research. One researcher reported relationships with AbbVie, AstraZeneca, MedImmune, Bayer, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche Canada, and Takeda. Dr. Karam-Hage reported having no relevant disclosures.
SOURCE: Fares AF et al. ASCO 2020, Abstract 1512.
This article was updated 5/15/20.
Quitting smoking prior to a lung cancer diagnosis is associated with a survival benefit, even among patients who recently stopped smoking, according to results of a pooled analysis.
The overall survival advantage was significant regardless of how long ago patients had last smoked, including among those who quit within 2 years prior to their diagnosis.
These findings create a “teachable moment” for health care providers in scenarios when patients might be more receptive to a stop-smoking message, according to investigator Aline F. Fares, MD, a clinical research fellow at Princess Margaret Cancer Centre in Toronto.
“Our study can be summarized to patients as, ‘it’s never too late to quit,’ ” Dr. Fares said.
She presented results from this study at the American Society of Clinical Oncology virtual scientific program during a press briefing in advance of the meeting. This year, ASCO’s annual meeting is split into two parts. The virtual scientific program will be presented online May 29-31. The virtual education program will be available Aug. 8-10.
Results
Dr. Fares presented data on 35,481 patients with a diagnosis of lung cancer who had been enrolled in 17 studies conducted by the International Lung Cancer Consortium. (Data in the presentation were updated from the abstract.)
At diagnosis, 47.5% of the patients were current smokers, 30% were former smokers, and 22.5% were never smokers.
The risk of death from any cause was cut by 20% among former smokers who quit more than 5 years before their lung cancer diagnosis (P < .001). Patients who quit smoking 2-5 years before diagnosis had a 16% reduction in the risk of death, while those who quit within 2 years of diagnosis had a 12% reduced risk (P < .001 for both comparisons).
The overall survival advantage was evident in this pooled analysis regardless of patient sex, disease stage, histology, or amount of smoking as measured in pack-years, according to Dr. Fares. That said, the overall survival advantage appeared to be even greater among heavier smokers (i.e., greater than 30 pack-years) as compared with lighter smokers.
Lung cancer–specific survival was improved by 15% for patients who quit smoking more than 5 years prior to their diagnosis. For those who had quit more recently, there was a nonsignificant trend toward improvement in this outcome.
Overall survival was higher in never smokers in comparison with current smokers, a finding that was expected based on previous studies, according to Dr. Fares.
Implications
These findings could be important to share with individuals who are current smokers at the time of lung cancer screening, according to Maher A. Karam-Hage, MD, medical director of the tobacco treatment program at the University of Texas MD Anderson Cancer Center, Houston.
“The power of this data is that it shows quitting makes a difference, and that it can be more impactful the longer you quit before you get diagnosed,” Dr. Karam-Hage said in an interview.
Negative lung cancer screening results sometimes give individuals the false impression that they are “one of the lucky ones” who won’t get lung cancer and don’t have to quit smoking, according to Dr. Karam-Hage, who is studying the comparative effectiveness of different smoking cessation strategies.
“Now, as part of shared decision making, we can provide people with specific numbers before the scan that [suggest] no matter what the scan comes out with, the earlier they quit, the better off they will be,” he said.
In her presentation, Dr. Fares said that lung cancer screening may be an “interesting time” to address smoking cessation, particularly among patients with a heavier smoking history.
“After a lifetime of smoking, patients often feel it’s too late to quit smoking and that the damage has already been done,” she added.
The International Lung Cancer Consortium studies had multiple supporters. Dr. Fares reported having no disclosures related to the research. One researcher reported relationships with AbbVie, AstraZeneca, MedImmune, Bayer, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche Canada, and Takeda. Dr. Karam-Hage reported having no relevant disclosures.
SOURCE: Fares AF et al. ASCO 2020, Abstract 1512.
This article was updated 5/15/20.
Quitting smoking prior to a lung cancer diagnosis is associated with a survival benefit, even among patients who recently stopped smoking, according to results of a pooled analysis.
The overall survival advantage was significant regardless of how long ago patients had last smoked, including among those who quit within 2 years prior to their diagnosis.
These findings create a “teachable moment” for health care providers in scenarios when patients might be more receptive to a stop-smoking message, according to investigator Aline F. Fares, MD, a clinical research fellow at Princess Margaret Cancer Centre in Toronto.
“Our study can be summarized to patients as, ‘it’s never too late to quit,’ ” Dr. Fares said.
She presented results from this study at the American Society of Clinical Oncology virtual scientific program during a press briefing in advance of the meeting. This year, ASCO’s annual meeting is split into two parts. The virtual scientific program will be presented online May 29-31. The virtual education program will be available Aug. 8-10.
Results
Dr. Fares presented data on 35,481 patients with a diagnosis of lung cancer who had been enrolled in 17 studies conducted by the International Lung Cancer Consortium. (Data in the presentation were updated from the abstract.)
At diagnosis, 47.5% of the patients were current smokers, 30% were former smokers, and 22.5% were never smokers.
The risk of death from any cause was cut by 20% among former smokers who quit more than 5 years before their lung cancer diagnosis (P < .001). Patients who quit smoking 2-5 years before diagnosis had a 16% reduction in the risk of death, while those who quit within 2 years of diagnosis had a 12% reduced risk (P < .001 for both comparisons).
The overall survival advantage was evident in this pooled analysis regardless of patient sex, disease stage, histology, or amount of smoking as measured in pack-years, according to Dr. Fares. That said, the overall survival advantage appeared to be even greater among heavier smokers (i.e., greater than 30 pack-years) as compared with lighter smokers.
Lung cancer–specific survival was improved by 15% for patients who quit smoking more than 5 years prior to their diagnosis. For those who had quit more recently, there was a nonsignificant trend toward improvement in this outcome.
Overall survival was higher in never smokers in comparison with current smokers, a finding that was expected based on previous studies, according to Dr. Fares.
Implications
These findings could be important to share with individuals who are current smokers at the time of lung cancer screening, according to Maher A. Karam-Hage, MD, medical director of the tobacco treatment program at the University of Texas MD Anderson Cancer Center, Houston.
“The power of this data is that it shows quitting makes a difference, and that it can be more impactful the longer you quit before you get diagnosed,” Dr. Karam-Hage said in an interview.
Negative lung cancer screening results sometimes give individuals the false impression that they are “one of the lucky ones” who won’t get lung cancer and don’t have to quit smoking, according to Dr. Karam-Hage, who is studying the comparative effectiveness of different smoking cessation strategies.
“Now, as part of shared decision making, we can provide people with specific numbers before the scan that [suggest] no matter what the scan comes out with, the earlier they quit, the better off they will be,” he said.
In her presentation, Dr. Fares said that lung cancer screening may be an “interesting time” to address smoking cessation, particularly among patients with a heavier smoking history.
“After a lifetime of smoking, patients often feel it’s too late to quit smoking and that the damage has already been done,” she added.
The International Lung Cancer Consortium studies had multiple supporters. Dr. Fares reported having no disclosures related to the research. One researcher reported relationships with AbbVie, AstraZeneca, MedImmune, Bayer, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche Canada, and Takeda. Dr. Karam-Hage reported having no relevant disclosures.
SOURCE: Fares AF et al. ASCO 2020, Abstract 1512.
This article was updated 5/15/20.
FROM ASCO 2020